Download PDF
Semin intervent Radiol 2018; 35(01): 029-034
DOI: 10.1055/s-0038-1636518
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers

Samdeep K. Mouli
1   Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
,
Ramona Gupta
1   Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
,
Neil Sheth
1   Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
,
Andrew C. Gordon
1   Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
,
Robert J. Lewandowski
1   Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
2   Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, Illinois
3   Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
05 April 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Breast cancer is the most common women's malignancy in the United States and is the second leading cause of cancer death. More than half of patients with breast cancer will develop hepatic metastases; this portends a poorer prognosis. In the appropriately selected patient, there does appear to be a role for curative (surgery, ablation) or palliative (intra-arterial treatments) locoregional therapy. Gynecologic malignancies are less common and metastases to the liver are most often seen in the setting of disseminated disease. The role of locoregional therapies in these patients is not well reported. The purpose of this article is to review the outcomes data of locoregional therapies in the treatment of hepatic metastases from breast and gynecologic malignancies.

Keywords

breast cancer - gynecologic malignancies - liver metastases - chemoembolization - radioembolization - interventional radiology
 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67 (01) 7-30
    CrossrefPubMedGoogle Scholar
  • 2 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (02) 69-90
    CrossrefPubMedGoogle Scholar
  • 3 Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987; 5 (05) 773-782
    CrossrefPubMedGoogle Scholar
  • 4 Atalay G, Biganzoli L, Renard F. , et al; EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39 (17) 2439-2449
    CrossrefPubMedGoogle Scholar
  • 5 Cummings MC, Simpson PT, Reid LE. , et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol 2014; 232 (01) 23-31
    CrossrefPubMedGoogle Scholar
  • 6 Chi DS, Fong Y, Venkatraman ES, Barakat RR. Hepatic resection for metastatic gynecologic carcinomas. Gynecol Oncol 1997; 66 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 7 Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 1997; 67 (01) 56-60
    CrossrefPubMedGoogle Scholar
  • 8 Kim GE, Lee SW, Suh CO. , et al. Hepatic metastases from carcinoma of the uterine cervix. Gynecol Oncol 1998; 70 (01) 56-60
    CrossrefPubMedGoogle Scholar
  • 9 Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005; 19 (08) 1057-1063 , discussion 1063–1064, 1069
    PubMedGoogle Scholar
  • 10 Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008; 9 (11) 1092-1101
    CrossrefPubMedGoogle Scholar
  • 11 Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008; 9 (12) 1181-1190
    CrossrefPubMedGoogle Scholar
  • 12 Gradishar WJ, Anderson BO, Balassanian R. , et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw 2017; 15 (04) 433-451
    CrossrefPubMedGoogle Scholar
  • 13 Golse N, Adam R. Liver metastases from breast cancer: what role for surgery? Indications and results. Clin Breast Cancer 2017; 17 (04) 256-265
    CrossrefPubMedGoogle Scholar
  • 14 Elsberger B, Roxburgh CS, Horgan PG. Is there a role for surgical resections of hepatic breast cancer metastases?. Hepatogastroenterology 2014; 61 (129) 181-186
    PubMedGoogle Scholar
  • 15 Vogl TJ, Farshid P, Naguib NN, Zangos S. Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur Radiol 2013; 23 (03) 797-804
    CrossrefPubMedGoogle Scholar
  • 16 Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 2001; 220 (01) 145-149
    CrossrefPubMedGoogle Scholar
  • 17 Lawes D, Chopada A, Gillams A, Lees W, Taylor I. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg Engl 2006; 88 (07) 639-642
    CrossrefPubMedGoogle Scholar
  • 18 Gunabushanam G, Sharma S, Thulkar S. , et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol 2007; 18 (1, Pt 1): 67-72
    CrossrefPubMedGoogle Scholar
  • 19 Sofocleous CT, Nascimento RG, Gonen M. , et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007; 189 (04) 883-889
    CrossrefPubMedGoogle Scholar
  • 20 Jakobs TF, Hoffmann RT, Schrader A. , et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009; 32 (01) 38-46
    CrossrefPubMedGoogle Scholar
  • 21 Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee Jr FT. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation–intermediate and long-term survival rates. Radiology 2009; 253 (03) 861-869
    CrossrefPubMedGoogle Scholar
  • 22 Carrafiello G, Fontana F, Cotta E. , et al. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases. Radiol Med (Torino) 2011; 116 (07) 1059-1066
    CrossrefPubMedGoogle Scholar
  • 23 Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. Ultraschall Med 2011; 32 (05) 492-496
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Liang P, Dong B, Yu X. , et al. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. AJR Am J Roentgenol 2003; 181 (05) 1319-1325
    CrossrefPubMedGoogle Scholar
  • 25 Hickey R, Mulcahy MF, Lewandowski RJ. , et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys 2014; 88 (05) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 26 Gordon AC, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for breast cancer liver metastases. J Vasc Interv Radiol 2016; 27 (09) 1316-1319
    CrossrefPubMedGoogle Scholar
  • 27 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011; 259 (03) 641-657
    CrossrefPubMedGoogle Scholar
  • 28 Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 2006; 17 (09) 1425-1439
    CrossrefPubMedGoogle Scholar
  • 29 Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
    CrossrefPubMedGoogle Scholar
  • 30 Lewandowski RJ, Sato KT, Atassi B. , et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30 (04) 571-592
    CrossrefPubMedGoogle Scholar
  • 31 Ang C, Jhaveri K, Patel D, Gewirtz A, Seidman A, Kemeny N. Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases. Breast J 2013; 19 (01) 96-99
    CrossrefPubMedGoogle Scholar
  • 32 Arai Y, Sone Y, Inaba Y, Ariyoshi Y, Kido C. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother Pharmacol 1994; 33 (Suppl): S142-S144
    CrossrefPubMedGoogle Scholar
  • 33 Nielsen DL, Nørgaard H, Vestermark LW. , et al. Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. Breast 2012; 21 (04) 556-561
    CrossrefPubMedGoogle Scholar
  • 34 Vogl TJ, Naguib NNN, Nour-Eldin N-EA, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 2010; 20 (01) 173-180
    CrossrefPubMedGoogle Scholar
  • 35 Vogl TJ, Naguib NN, Nour-Eldin NE. , et al. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR Am J Roentgenol 2011; 196 (01) W66-72
    CrossrefPubMedGoogle Scholar
  • 36 Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 2013; 82 (12) e816-e822
    CrossrefPubMedGoogle Scholar
  • 37 Cho SW, Kitisin K, Buck D. , et al. Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. Int J Surg Oncol 2010; 2010: 251621
    CrossrefPubMedGoogle Scholar
  • 38 Martin RCG, Robbins K, Fagés JF. , et al. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat 2012; 132 (02) 753-763
    CrossrefPubMedGoogle Scholar
  • 39 Lin Y-T, Médioni J, Amouyal G, Déan C, Sapoval M, Pellerin O. Doxorubicin-loaded 70-150 μm microspheres for liver-dominant metastatic breast cancer: results and outcomes of a pilot study. Cardiovasc Intervent Radiol 2017; 40 (01) 81-89
    CrossrefPubMedGoogle Scholar
  • 40 Haug AR, Tiega Donfack BP, Trumm C. , et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53 (03) 371-377
    CrossrefPubMedGoogle Scholar
  • 41 Cianni R, Pelle G, Notarianni E. , et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013; 23 (01) 182-189
    CrossrefPubMedGoogle Scholar
  • 42 Jakobs TF, Hoffmann R-T, Fischer T. , et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19 (05) 683-690
    CrossrefPubMedGoogle Scholar
  • 43 Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol 2014; 21 (04) 1296-1303
    CrossrefPubMedGoogle Scholar
  • 44 Gordon AC, Gradishar WJ, Kaklamani VG. , et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol 2014; 25 (10) 1523-1532 , 1532.e1–1532.e2
    CrossrefPubMedGoogle Scholar
  • 45 Fendler WP, Lechner H, Todica A. , et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med 2016; 57 (04) 517-523
    CrossrefPubMedGoogle Scholar
  • 46 Pieper CC, Meyer C, Wilhelm KE. , et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases—a single-center experience. J Vasc Interv Radiol 2016; 27 (09) 1305-1315
    CrossrefPubMedGoogle Scholar
  • 47 Forstner R. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 2007; 17 (12) 3223-3235
    CrossrefPubMedGoogle Scholar
  • 48 Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol 2009; 112 (01) 22-27
    CrossrefPubMedGoogle Scholar
  • 49 Cormio G, Rossi C, Cazzolla A. , et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 2003; 13 (02) 125-129
    CrossrefPubMedGoogle Scholar
  • 50 Tangjitgamol S, Levenback CF, Beller U, Kavanagh JJ. Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 2004; 14 (03) 399-422
    CrossrefPubMedGoogle Scholar
  • 51 Kurra V, Krajewski KM, Jagannathan J, Giardino A, Berlin S, Ramaiya N. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging 2013; 13 (01) 113-122
    CrossrefPubMedGoogle Scholar
  • 52 Lim MC, Kang S, Lee KS. , et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol 2009; 112 (01) 28-34
    CrossrefPubMedGoogle Scholar
  • 53 Bosquet JG, Merideth MA, Podratz KC, Nagorney DM. Hepatic resection for metachronous metastases from ovarian carcinoma. HPB 2006; 8 (02) 93-96
    CrossrefPubMedGoogle Scholar
  • 54 Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 2003; 89 (01) 16-21
    CrossrefPubMedGoogle Scholar
  • 55 Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997; 64 (01) 4-8
    CrossrefPubMedGoogle Scholar
  • 56 Vogl TJ, Naguib NN, Lehnert T. , et al. Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management. Gynecol Oncol 2012; 124 (02) 225-229
    CrossrefPubMedGoogle Scholar
  • 57 Sato KT, Lewandowski RJ, Mulcahy MF. , et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 2008; 247 (02) 507-515
    CrossrefPubMedGoogle Scholar